论文部分内容阅读
目的:为利奈唑胺在新生儿人群中的合理使用提供参考。方法:归纳总结近年来国内外相关文献,主要对利奈唑胺治疗新生儿感染性疾病的药动学及给药方案、临床疗效及不良反应等问题进行归纳总、分析评述。结果:利奈唑胺在新生儿人群日龄<7 d和>7 d的药动学及给药方案存在差异,临床疗效方面利奈唑胺治疗MRSA和MRSE的有效率与万古霉素相当,而不良反应发生率比万古霉素低,但也需密切监测其血液毒性。有很多个案报道利奈唑胺成功救治糖肽类药物治疗失败的G~+菌感染的新生儿。结论:利奈唑胺是治疗新生儿G~+球菌感染较安全的二线药物。
Objective: To provide a reference for the rational use of linezolid in newborns. Methods: To summarize the relevant literatures at home and abroad in recent years, mainly summarize the pharmacokinetics and administration of linezolid for the treatment of neonatal infectious diseases, clinical efficacy and adverse reactions. Results: Linezolid had no difference in the pharmacokinetics and dosage regimen between day 7 and day 7 in neonates. The clinical efficacy of linezolid in the treatment of MRSA and MRSE was comparable to that of vancomycin, The incidence of reactions is lower than that of vancomycin but close monitoring of its blood toxicity is also required. There are many cases reported that linezolid was successfully treated glycopeptide drug treatment failed G ~ + infection in newborns. Conclusion: Linezolid is a safe second-line drug for the treatment of neonatal G ~ + cocci infection.